From guideline to practice: New shared decision‐making tools for colorectal cancer screening from the American Cancer Society

Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society

“…The ACS will seek to mitigate the impact of conflicting recommendations through clear communication of its recommendation and rationale, including provider and patient support materials (http://cancer.org/colonmd). Second, there will likely be a lag between the publication of this recommendation and insurance coverage by all providers of CRC screening starting at age 45 years. The 2010 ACA requires that nongrandfathered commercial insurance plans fully cover USPSTF‐recommended screening tests; these are minimum coverage standards for an ACA‐qualified health plan, and plans are not restricted from extending CRC screening coverage to individuals aged 45 to 49 years.…”

“…The information provided is designed to facilitate clinician‐patient encounters and patient choices consistent with their preferences and thus increase utilization of CRC screening. In addition, materials to facilitate test selection at the point of care have been developed by the ACS …”

“…This guideline provides a list of options for CRC screening along with considerations for decision making to assist health professionals and patients in selecting the option most likely to be completed (Table ). In addition, a clinicians' guide and decision support materials have been developed to accompany this guideline to facilitate the decision‐making process . It is anticipated that these materials will help both uptake of and adherence to CRC screening by better aligning the selected screening test with patient preferences.…”

Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening

“…The 2018 CRC screening guideline does not prioritize among screening tests, emphasizing instead that screening utilization and adherence could be improved by offering a choice of tests at the time of referral to CRC screening. Health professionals should provide guidance to adults about the benefits, limitations, and burdens associated with screening test options to assist them in making a choice and completing screening . For example, when advising patients about gFOBT or FIT, it is important to stress that there must be a commitment to annual at‐home testing with adherence to manufacturer's instructions, or the limited sensitivity observed with one‐time testing would make stool testing a poor choice.…”

Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening

“…In contrast to the 2008 ACS guideline, which prioritized screening options that had a higher potential to prevent CRC through the detection of adenomatous polyps, the 2018 CRC screening guideline does not prioritize among screening tests, emphasizing instead that screening utilization and adherence could be improved by offering a choice of tests at the time of referral to CRC screening. Health professionals should provide guidance to adults about the benefits, limitations, and potential burdens associated with screening test options and assist them in making a choice and completing screening . For example, when advising patients about gFOBT or FIT, it is important to stress that there must be a commitment to annual at‐home testing with adherence to manufacturer's instructions, or the limited sensitivity observed with one‐time testing would make stool testing a poor choice.…”